Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/10/2025

Heparin-Induced Thrombocytopenia Monitoring

Introduction to HIT Monitoring

  • The American College of Chest Physicians recommends monitoring platelet counts every 2-3 days from day 4 to day 14 for surgical and trauma patients receiving unfractionated heparin (UFH), and every 2-4 days for medical and obstetric patients receiving UFH or postoperative low molecular weight heparin (LMWH) 1
  • The American College of Chest Physicians recommends no routine platelet monitoring beyond baseline for medical patients receiving only LMWH 1

Special Considerations for HIT Monitoring

  • For patients who received heparin within the previous 100 days, the American College of Chest Physicians recommends obtaining a baseline platelet count and a repeat count 24 hours after starting heparin 1
  • For patients who develop acute inflammatory reactions or cardiorespiratory symptoms within 30 minutes of IV heparin bolus, the American College of Chest Physicians recommends performing an immediate platelet count 1
  • If a patient received heparin within the previous 30-100 days, beginning platelet count monitoring on day 0 (day of initiation) and obtaining a repeat platelet count at 24 hours if feasible, is suggested 1
  • If a patient received heparin within the previous 30 days, begin platelet count monitoring on day 0 (day of heparin initiation), according to the American College of Cardiology 2

Key Indicators for HIT Evaluation

  • A platelet count drop of ≥50% from baseline should prompt immediate HIT evaluation, as recommended by the American College of Chest Physicians 1
  • New thrombotic events while on heparin should prompt immediate HIT evaluation, as recommended by the American College of Chest Physicians 1
  • Skin necrosis or unusual reactions after heparin injection should prompt immediate HIT evaluation, as recommended by the American College of Chest Physicians 1
  • The American Society of Hematology and the American College of Chest Physicians recommend platelet count monitoring for HIT, stratified by patient risk category:

    Patient Risk Category Monitoring Schedule
    Low-risk no routine monitoring
    Intermediate-risk twice weekly monitoring from days 4-14
    High-risk every-other-day monitoring from days 4-14

Monitoring Schedules

  • Medical, obstetric, surgical, and trauma patients receiving heparin should have their platelet counts monitored according to the following schedules:

    Patient Type Monitoring Schedule
    Medical and obstetric once to twice weekly from day 4 to day 14, then weekly for one month if heparin therapy continues
    Surgical and trauma every other day (2-3 times weekly) from day 4 to day 14, then weekly for one month if heparin therapy continues
  • Monitoring of hemoglobin, hematocrit, and platelet count should be performed every 2-3 days up to at least day 14, then every 2 weeks thereafter, as recommended by the National Comprehensive Cancer Network (NCCN) 4

Baseline Laboratory Tests and Contraindications

  • Baseline laboratory tests should include complete blood count (CBC) with platelet count, activated partial thromboplastin time (aPTT), prothrombin time (PT)/International Normalized Ratio (INR) if patient is on or will transition to warfarin, and serum creatinine and creatinine clearance, especially if renal dysfunction is suspected 2
  • Contraindications to subcutaneous heparin therapy include active major bleeding, severe thrombocytopenia, recent spinal anesthesia/lumbar puncture, and intracranial or spinal lesions at high risk for bleeding, according to the National Comprehensive Cancer Network (NCCN) 4

Management of Suspected HIT

  • If HIT is suspected, immediately discontinue all heparin products, calculate the 4T score to determine clinical probability of HIT, order appropriate laboratory testing, and initiate alternative anticoagulation with a direct thrombin inhibitor or factor Xa inhibitor, as recommended by the American Society of Hematology 3
  • Avoid vitamin K antagonists until platelet count has substantially recovered, and perform lower extremity ultrasound to evaluate for occult deep vein thrombosis, according to the American College of Cardiology 3
  • The strength of evidence for these recommendations is based on expert opinion and clinical experience, with a moderate to high level of evidence supporting the importance of baseline laboratory testing and monitoring for HIT risk 2